Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. EMA publishes revised guidelines on antibacterial drug development
  2. The Future of Pfizer’s $5B Brand is in Jeopardy
  3. Industry Viewpoints: The Continual Rise of Direct-to-Patient
  4. Clear Clinical Trial Information is the Key to Patient Engagement
  5. The Top 5: July 2018

Latest Content

Dealing with the unexpected: Covid-19 and risk management

Major global events such as the ongoing Covid-19 pandemic can cause significant problems for clinical trials and pharma research programmes. Oncoinvent head of clinical operations Helén Johansen Blanco shares her expertise on proactive risk management and when a risk becomes an issue.

August’s top news stories

Biopharmaceutical firm Retrophin reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients; and MyoKardia has commenced dosing of patients in a Phase I trial of small molecule MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM). wraps up the key headlines from August 2019.

Latest News


Go Top